<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62192">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02058836</url>
  </required_header>
  <id_info>
    <org_study_id>121364</org_study_id>
    <nct_id>NCT02058836</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin for the Management of Chronic Orchialgia</brief_title>
  <official_title>Botulinum Toxin for the Management of Chronic Orchialgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest Baptist Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest Baptist Health</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if Botox injections will provide relief
      from chronic testicular pain.  In the study, the spermatic cord of particpants will be
      injected with either Botox or a placebo of saline.  Botox is currently used to treat other
      urological conditions like overactive bladder and lower urinary tract problems.  For these
      conditions, Botox works by relaxing muscles in the affected areas.  The investigators
      believe that Botox will act similarly in the treatment chronic testicular pain.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual Analog Scale for Pain Score</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Visual Analog Scale for Pain Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale for Pain Score</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Visual Analog Scale for Pain Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale for Pain Score</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Visual Analog Scale for Pain Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale for Pain score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in Visual Analog Scale for Pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Questionnaire Score</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Quality of Life Questionnaire Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Questionnaire Score</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Quality of Life Questionnaire Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Questionnaire Score</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Quality of Life Questionnaire Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Questionnaire Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Quality of Life Questionnaire Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Units of Analgesics Used for Testicular Pain</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Units of Analgesics Used for Testicular Pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Units of Analgesics Used for Testicular Pain</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Units of Analgesics Used for Testicular Pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Units of Analgesics Used for Testicular Pain</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Units of Analgesics Used for Testicular Pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Units of Analgesics Used for Testicular Pain</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Units of Analgesics Used for Testicular Pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Testicular Pain</condition>
  <arm_group>
    <arm_group_label>Botox Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will be given an injection of Botox along the spermatic cord under ultrasound guidance.  Before drug administration, a nerve block using bupivacaine will be completed to numb the area for treatment.  This will be a 10 mL injection done one time at the initial patient visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient will receive an inactive injection of normal saline along the spermatic cord under ultrasound guidance. This will be a 10 ml injection done once at the initial visit. Before the injection of saline, a spermatic cord block using bupivacaine will be completed to numb the area for treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox Injection</intervention_name>
    <description>One-time injection of 100 Units of Botox in 10 mL of saline.  The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.</description>
    <arm_group_label>Botox Injection</arm_group_label>
    <other_name>Botox</other_name>
    <other_name>Botulinum toxin-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of chronic testicular pain (orchialgia)

        Exclusion Criteria:

          -  Active infection of urinary tract (UTI)

          -  Active infection of the scrotal skin of the affected side

          -  Bilateral orchiectomy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan P Terlecki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan P Terlecki, MD</last_name>
    <phone>336-716-2011</phone>
    <email>rterlecki@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ryan P Terlecki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew G Heavner, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest Baptist Health</investigator_affiliation>
    <investigator_full_name>Ryan Terlecki, MD</investigator_full_name>
    <investigator_title>Assitant Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>Chronic testicular pain</keyword>
  <keyword>Orchialgia</keyword>
  <keyword>Botulinum toxin</keyword>
  <keyword>Botox</keyword>
  <keyword>Urology</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
